In this last regard, it should be taken in mind that therapy with dopaminergic agonists (and possibly with l-DOPA and other indirect dopaminergic agents) could be also a confounding factor in studies of Th17/IL-17 in PD patients. Here, IL17A is linked to Parkinson disease.